Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma

Highlights • Squamous cell lung carcinoma accounts for ∼30% of all NSCLCs. • The PI3K/AKT/mTOR pathway is one of the most frequently altered pathways in cancer. • Many PI3K/AKT/mTOR pathway inhibitors are under clinical development for lung cancer. • We discuss the preliminary clinical activity obse...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2014-09, Vol.40 (8), p.980-989
Hauptverfasser:	Beck, Joseph Thaddeus, Ismail, Amen, Tolomeo, Christina
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences Biomarkers Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - enzymology Clinical Trials as Topic Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Medical sciences Molecular Targeted Therapy mTOR inhibitor Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Oncogene Protein v-akt - antagonists & inhibitors Oncogene Protein v-akt - metabolism Pharmacology. Drug treatments Phosphatidylinositol 3-Kinases - antagonists & inhibitors Phosphatidylinositol 3-Kinases - metabolism PI3K inhibitor PI3K/AKT/mTOR pathway Pneumology Protein Kinase Inhibitors - therapeutic use Signal Transduction - drug effects Squamous cell lung carcinoma TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - metabolism Tumors Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Squamous cell lung carcinoma accounts for ∼30% of all NSCLCs. • The PI3K/AKT/mTOR pathway is one of the most frequently altered pathways in cancer. • Many PI3K/AKT/mTOR pathway inhibitors are under clinical development for lung cancer. • We discuss the preliminary clinical activity observed with these inhibitors. • We also highlight the potential impact of predictive biomarkers and NGS.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2014.06.006